Cytokinetics Ownership

CYTK
 Stock
  

USD 47.77  0.47  0.99%   

Some institutional investors establish a significant position in stocks such as Cytokinetics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Cytokinetics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Continue to Trending Equities.
  
Refresh
The current Preferred Dividends Income Statement Impact is estimated to increase to about 1.5 M. The current Issuance Purchase of Equity Shares is estimated to increase to about 345.2 M, while Weighted Average Shares is projected to decrease to under 65.4 M.
Cytokinetics holds a total of eighty-four million three hundred ninety thousand outstanding shares. The majority of Cytokinetics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Cytokinetics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Cytokinetics. Please pay attention to any change in the institutional holdings of Cytokinetics as this could imply that something significant has changed or about to change at the company. Also note that nearly sixteen million thirty-four thousand one hundred invesors are currently shorting Cytokinetics expressing very little confidence in its future performance.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Cytokinetics Stock Ownership Analysis

About 114.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 3.11. Cytokinetics had not issued any dividends in recent years. The entity had 1:6 split on the 25th of June 2013. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people. For more info on Cytokinetics please contact Robert Blum at 650 624-3000 or go to www.cytokinetics.com.
Besides selling stocks to institutional investors, Cytokinetics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cytokinetics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cytokinetics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Cytokinetics Quarterly Share Based Compensation

8.98 Million

Share
About 5.0% of Cytokinetics are currently held by insiders. Unlike Cytokinetics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cytokinetics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%.

Cytokinetics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Cytokinetics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Cytokinetics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Cytokinetics specific information freely available to individual and institutional investors to make a timely investment decision.
17th of June 2022
Other Events
View
27th of May 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
14th of February 2022
Unclassified Corporate Event
View

Cytokinetics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytokinetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytokinetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cytokinetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Fady Malik over two weeks ago via Macroaxis 
Exercise or conversion by Fady Malik of 21500 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over two weeks ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over a month ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Fady Malik over a month ago via Macroaxis 
Exercise or conversion by Fady Malik of 13987 shares of Cytokinetics subject to Rule 16b-3
Harrington Robert Arthur over a month ago via Macroaxis 
Acquisition by Harrington Robert Arthur of 10000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over a month ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over two months ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Harrington Robert Arthur over two months ago via Macroaxis 
Acquisition by Harrington Robert Arthur of 35000 shares of Cytokinetics subject to Rule 16b-3
Fady Malik over two months ago via Macroaxis 
Exercise or conversion by Fady Malik of 23148 shares of Cytokinetics subject to Rule 16b-3
Ching Jaw over two months ago via Macroaxis 
Exercise or conversion by Ching Jaw of 10000 shares of Cytokinetics subject to Rule 16b-3
Robert Blum over three months ago via Macroaxis 
Exercise or conversion by Robert Blum of 10000 shares of Cytokinetics subject to Rule 16b-3
Mark Schlossberg over three months ago via Macroaxis 
Exercise or conversion by Mark Schlossberg of 25196 shares of Cytokinetics subject to Rule 16b-3

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Equity Valuation Now

   

Equity Valuation

Check real value of public entities based on technical and fundamental data
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.2 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.